Cangrelor sodium (ARC69931MX; AR-C69931; Kengreal, CANREAL; Kengrexal), the tetra-sodium salt of cangrelor which is an ATP analog, is a reversible, selective and direct-acting P2Y12 inhibitor approved in June 2015 as an antiplatelet drug for intravenous application. Cangrelor is a modified ATP analog that is stable against enzymatic degradation and does not require metabolic reaction to become an active metabolite, which is different from the prodrug clopidogrel (Plavix). This allows cangrelor's immediate effect after infusion, and the therapeutic effects can be maintained with continuous infusion.

纯度：≥98%

CAS：163706-36-3